Advertisement

Der Urologe

, Volume 54, Issue 11, pp 1578–1583 | Cite as

Testosteron im Management des metastasierten Prostatakarzinoms

  • J.M. WolffEmail author
  • H.P. Schmid
Übersichten
  • 252 Downloads

Zusammenfassung

Das Prostatakarzinom (PCa) ist der häufigste maligne Tumor und die dritthäufigste Krebstodesursache bei Männern in Deutschland. Die Funktion der Prostata wird durch Testosteron bzw. dessen Metabolit Dihydrotestosteron maßgeblich beeinflusst. Über die Bedeutung von Testosteron beim metastasierten kastrationsresistenten Prostatakarzinom (mCRPC) besteht jedoch vielfach Unklarheit. Lange Zeit wurde die Korrelation des Testosteronspiegels mit der Entstehung oder der Progredienz des PCa über die Androgenhypothese erklärt. Neuere Daten haben die Androgenhypothese jedoch infrage gestellt. Ein hoher Testosteronspiegel begünstigt die Entstehung oder Progredienz eines Prostatakarzinoms nicht und ein niedriger Testosteronspiegel wirkt nicht protektiv. Die Relevanz des Testosteronspiegels beim mCRPC zeigen u. a. die Ergebnisse aus den klinischen Zulassungsstudien mit neuen Substanzen wie Abirateronacetat und Enzalutamid. Die Hinweise auf einen prognostischen Charakter des Testosteronspiegels mehren sich.

Schlüsselwörter

Prostatakarzinom Testosteronspiegel Androgenentzugstherapie (ADT) Sättigungshypothese Kastrationsniveaus 

Testosterone in the management of metastatic prostate cancer

Abstract

Background

Among all cancer types, prostate cancer (PCa) is the most prevalent cancer and is the third-leading cause of cancer-related death in men. The biologic function of the prostate is decisively influenced by testosterone and its metabolic product dihydrotestosterone. However, there is general uncertainty about the role of testosterone in metastatic castration-resistant prostate cancer (mCRPC). For many years, the androgen hypothesis had been accepted to explain the correlation between testosterone levels and the development or progression of PCa. However, extensive study analyses revealed contradictory results, leading to a reconsideration of the androgen hypothesis. High serum testosterone levels do not predispose to PCa development and low serum testosterone levels are not protective. The importance of testosterone levels in patients with mCRPC has been shown in several registration studies with new drugs, such as abiraterone acetate and enzalutamide. There is growing evidence suggesting a prognostic role of testosterone levels in mCRPC.

Keywords

Prostate cancer Testosterone levels Androgen deprivation therapy (ADT) Saturation model Castration levels 

Notes

Danksagung

Die Autoren danken Dr. M. Esser und Dr. J. Schreier (co.faktor GmbH, Berlin) für die Unterstützung bei der Manuskripterstellung.

Einhaltung ethischer Richtlinien

Interessenkonflikt

J. M. Wolff: Referenten- und Beratertätigkeit für die Firmen Amgen, Apogepha, Astellas, AstraZeneca, Bayer, Ferring, Hexal, Ipsen, Janssen, Sanofi und Takeda. P.-P. Schmid: Beratertätigkeit für Astellas, Janssen, Sanofi und Takeda.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Attard G, Reid AH, A’Hern R et al (2009) Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27:3742–3748PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Barrie SE, Haynes BP, Potter GA et al (1997) Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. J Steroid Biochem Mol Biol 60:347–351CrossRefPubMedGoogle Scholar
  3. 3.
    Calof OM, Singh AB, Lee ML et al (2005) Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 60:1451–1457CrossRefPubMedGoogle Scholar
  4. 4.
    Chen CD, Welsbie DS, Tran C et al (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33–39CrossRefPubMedGoogle Scholar
  5. 5.
    Cooper CS, Perry PJ, Sparks AE et al (1998) Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol 159:441–443CrossRefPubMedGoogle Scholar
  6. 6.
    Crawford ED, Eisenberger MA, McLeod DG et al (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419–424CrossRefPubMedGoogle Scholar
  7. 7.
    Efstathiou E, Titus M, Wen S et al (2014) Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur UrolGoogle Scholar
  8. 8.
    Fizazi K, Scher HI, Molina A et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983–992CrossRefPubMedGoogle Scholar
  9. 9.
    Geller J, Albert JD, Nachtsheim DA, Loza D (1984) Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J Urol 132:693–696PubMedGoogle Scholar
  10. 10.
    Halabi S, Small EJ, Kantoff PW et al (2003) Prognostic model for predicting survival in men with hormone- refractory metastatic prostate cancer. J Clin Oncol 21:1232–1237CrossRefPubMedGoogle Scholar
  11. 11.
    Holzbeierlein J, Lal P, LaTulippe E et al (2004) Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164:217–227PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Huggins C, Stevens RE, Hodges CV (1941) Studies on prostatic cancer II. The effects of castration on advanced carcinoma of the prostate. Arch Surg 43:209–223CrossRefGoogle Scholar
  13. 13.
    Isbarn H, Pinthus JH, Marks LS et al (2009) Testosterone and prostate cancer: revisiting old paradigms. Eur Urol 56:48–56CrossRefPubMedGoogle Scholar
  14. 14.
    Jarman M, Barrie SE, Llera JM (1998) The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16- dien-3beta-ol) and related steroidal inhibitors. J Med Chem 41:5375–5381CrossRefPubMedGoogle Scholar
  15. 15.
    Jastrzebska S, Walczak-Jedrzejowska R, Kramek E et al (2014) Relationship between sexual function, body mass index and levels of sex steroid hormones in young men. Endokrynol Pol 65:203–209CrossRefPubMedGoogle Scholar
  16. 16.
    Khera M, Crawford D, Morales A et al (2014) A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol 65:115–123CrossRefPubMedGoogle Scholar
  17. 17.
    Kim J, Coetzee GA (2004) Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem 93:233–241CrossRefPubMedGoogle Scholar
  18. 18.
    Klotz L, Nabid A, Higano C et al (2014) Effect of dutasteride in men receiving intermittent androgen ablation therapy: the AVIAS trial. Can Urol Assoc J 8:E789–E794PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Klotz L, O’Callaghan C, Dearnaley D et al (2014) Nadir testosterone (T) on ADT predicts for time to castrate resistant progression: a secondary analysis of the PR-7 intermittent vs continuous ADT trial. In: 29th Annual European Association of Urology (EAU) Congress. StockholmGoogle Scholar
  20. 20.
    Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF) (2014) Konsultationsfassung: Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 2.2; AWMF Registernummer: 034/022OL. http://leitlinienprogramm-onklogie.de/Leitlinien.7.0.htmlGoogle Scholar
  21. 21.
    Miyatake A, Morimoto Y, Oishi T et al (1980) Circadian rhythm of serum testosterone and its relation to sleep: comparison with the variation in serum luteinizing hormone, prolactin, and cortisol in normal men. J Clin Endocrinol Metab 51:1365–1371CrossRefPubMedGoogle Scholar
  22. 22.
    Molina A, Belldegrun A (2011) Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol 185:787–794CrossRefPubMedGoogle Scholar
  23. 23.
    Morgentaler A (2006) Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 50:935–939CrossRefPubMedGoogle Scholar
  24. 24.
    Morgentaler A, Traish AM (2009) Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 55:310–320CrossRefPubMedGoogle Scholar
  25. 25.
    Mostaghel EA, Page ST, Lin DW et al (2007) Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67:5033–5041CrossRefPubMedGoogle Scholar
  26. 26.
    Mottet N, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. http://www.uroweb.orgGoogle Scholar
  27. 27.
    Muller RL, Gerber L, Moreira DM et al (2012) Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the reduction by dutasteride of prostate cancer events trial. Eur Urol 62:757–764CrossRefPubMedGoogle Scholar
  28. 28.
    Rathkopf DE, Smith MR, Bono JS de et al (2014) Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 66(5):815–825PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Roder MA, Christensen IJ, Berg KD et al (2012) Serum testosterone level as a predictor of biochemical failure after radical prostatectomy for localized prostate cancer. BJU Int 109:520–524CrossRefPubMedGoogle Scholar
  30. 30.
    Rosner W, Auchus RJ, Azziz R et al (2007) Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 92:405–413CrossRefPubMedGoogle Scholar
  31. 31.
    Rosner W, Vesper H (2008) Preface. CDC workshop report improving steroid hormone measurements in patient care and research translation. Steroids 73:1285CrossRefPubMedGoogle Scholar
  32. 32.
    Rosner W, Vesper H (2010) Toward excellence in testosterone testing: a consensus statement. J Clin Endocrinol Metab 95:4542–4548CrossRefPubMedGoogle Scholar
  33. 33.
    Ryan CJ (2014) Final analysis of phase 3 COU-AA-302 study. In: European Society for Medical Oncology (ESMO). Madrid, p abstract 753OGoogle Scholar
  34. 34.
    Ryan CJ, Cheng ML (2013) Abiraterone acetate for the treatment of prostate cancer. Expert Opin Pharmacother 14:91–96CrossRefPubMedGoogle Scholar
  35. 35.
    Ryan CJ, Molina A, Li J et al (2013) Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol 31:2791–2798CrossRefPubMedGoogle Scholar
  36. 36.
    Ryan CJ, Peng W, Kheoh T et al (2014) Androgen dynamics and serum PSA in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis 17:192–198PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Ryan CJ, Smith MR, Bono JS de et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138–148PubMedCentralCrossRefPubMedGoogle Scholar
  38. 38.
    Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148–1159PubMedCentralCrossRefPubMedGoogle Scholar
  39. 39.
    Shaneyfelt T, Husein R, Bubley G, Mantzoros CS (2000) Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 18:847–853PubMedGoogle Scholar
  40. 40.
    Tindall DJ, Rittmaster RS (2008) The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol 179:1235–1242PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Titus MA, Schell MJ, Lih FB et al (2005) Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11:4653–4657CrossRefPubMedGoogle Scholar
  42. 42.
    Traish AM, Miner MM, Morgentaler A, Zitzmann M (2011) Testosterone deficiency. Am J Med 124:578–587CrossRefPubMedGoogle Scholar
  43. 43.
    Wang C, Catlin DH, Demers LM et al (2004) Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 89:534–543CrossRefPubMedGoogle Scholar
  44. 44.
    Wilson EM (2014) More evidence intratumoral DHT synthesis drives castration-resistant prostate cancer. Asian J Androl 16:99–100PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Urologische KlinikParacelsus-Klinik GolzheimDüsseldorfDeutschland
  2. 2.Kantonsspital St. GallenSt. GallenSchweiz

Personalised recommendations